CA3132318A1 - Compounds for prevention and treatment of obesity and related disorders - Google Patents
Compounds for prevention and treatment of obesity and related disorders Download PDFInfo
- Publication number
- CA3132318A1 CA3132318A1 CA3132318A CA3132318A CA3132318A1 CA 3132318 A1 CA3132318 A1 CA 3132318A1 CA 3132318 A CA3132318 A CA 3132318A CA 3132318 A CA3132318 A CA 3132318A CA 3132318 A1 CA3132318 A1 CA 3132318A1
- Authority
- CA
- Canada
- Prior art keywords
- methyl
- compound
- subject
- day
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962812314P | 2019-03-01 | 2019-03-01 | |
| US62/812,314 | 2019-03-01 | ||
| PCT/US2020/020707 WO2020180821A1 (en) | 2019-03-01 | 2020-03-02 | Compounds for prevention and treatment of obesity and related disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3132318A1 true CA3132318A1 (en) | 2020-09-10 |
Family
ID=72338080
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3132318A Pending CA3132318A1 (en) | 2019-03-01 | 2020-03-02 | Compounds for prevention and treatment of obesity and related disorders |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US12357596B2 (https=) |
| EP (1) | EP3931179B1 (https=) |
| JP (1) | JP7598195B2 (https=) |
| CN (1) | CN114072376B (https=) |
| CA (1) | CA3132318A1 (https=) |
| ES (1) | ES3059224T3 (https=) |
| WO (1) | WO2020180821A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024249415A1 (en) * | 2023-05-26 | 2024-12-05 | Abrexa Pharmaceuticals, Inc. | Compounds for use in organ preservation and organ transplantation |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4017540A (en) * | 1968-03-04 | 1977-04-12 | The Upjohn Company | Method of use, composition, and compounds |
| US20100004302A1 (en) * | 2003-04-29 | 2010-01-07 | Connie Erickson-Miller | Methods for Treating Degenerative Diseases/Injuries |
| US20070238700A1 (en) * | 2006-04-10 | 2007-10-11 | Winzenberg Kevin N | N-phenyl-1,1,1-trifluoromethanesulfonamide hydrazone derivative compounds and their usage in controlling parasites |
| US8779002B2 (en) * | 2007-10-15 | 2014-07-15 | Salk Institute For Biological Studies | Methods for treating a variety of diseases and conditions, and compounds useful therefor |
| WO2017112701A1 (en) * | 2015-12-22 | 2017-06-29 | Zogenix International Limited | Metabolism resistant fenfluramine analogs and methods of using the same |
-
2020
- 2020-03-02 EP EP20767302.1A patent/EP3931179B1/en active Active
- 2020-03-02 ES ES20767302T patent/ES3059224T3/es active Active
- 2020-03-02 CN CN202080030234.4A patent/CN114072376B/zh active Active
- 2020-03-02 CA CA3132318A patent/CA3132318A1/en active Pending
- 2020-03-02 US US17/435,678 patent/US12357596B2/en active Active
- 2020-03-02 JP JP2021551942A patent/JP7598195B2/ja active Active
- 2020-03-02 WO PCT/US2020/020707 patent/WO2020180821A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| EP3931179A1 (en) | 2022-01-05 |
| CN114072376A (zh) | 2022-02-18 |
| WO2020180821A1 (en) | 2020-09-10 |
| ES3059224T3 (en) | 2026-03-19 |
| EP3931179C0 (en) | 2025-12-10 |
| CN114072376B (zh) | 2024-12-20 |
| US12357596B2 (en) | 2025-07-15 |
| EP3931179A4 (en) | 2022-11-30 |
| US20220133657A1 (en) | 2022-05-05 |
| JP2022523792A (ja) | 2022-04-26 |
| JP7598195B2 (ja) | 2024-12-11 |
| EP3931179B1 (en) | 2025-12-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10905683B2 (en) | Compositions and uses of amidine derivatives | |
| EP3931178B1 (en) | Compounds for prevention and treatment of post-operative cognitive dysfunction | |
| BRPI0922806B1 (pt) | Composição farmacêutica oral compreendendo bendamustina | |
| JP7740810B2 (ja) | 呼吸困難に起因する集中治療後の認知機能障害及び認知障害の予防及び治療のための化合物 | |
| CN1530102B (zh) | 含有α-硫辛酸、氨溴索和/或血管紧张素转化酶(ACE)抑制剂的药物制剂及其治疗神经变性疾病的用途 | |
| KR20160003652A (ko) | 감마―글루타밀 주기 조절 방법 및 조성물 | |
| US12357596B2 (en) | Compounds for prevention and treatment of obesity and related disorders | |
| AU2019317518A1 (en) | Novel MCT4 inhibitors and uses thereof | |
| US11186534B2 (en) | Derivatives of sulindac can protect normal cells against oxidative damage | |
| US11938104B1 (en) | Compositions and methods for prevention and treatment of coronavirus and related disorders | |
| WO2024249415A1 (en) | Compounds for use in organ preservation and organ transplantation | |
| US12496281B2 (en) | Compounds for prevention and treatment of hemorrhage and vasculature instability | |
| HK40089435A (zh) | 预防和治疗重症监护後认知功能障碍和呼吸窘迫致认知功能障碍的化合物 | |
| HK40095617A (zh) | 用於预防和治疗出血和脉管系统不稳定的化合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20231219 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D120 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: VOLUNTARY SUBMISSION OF PRIOR ART RECEIVED Effective date: 20240821 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241203 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241203 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241203 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250226 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250319 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D123 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIOR ART DISCLOSURE DETERMINED COMPLIANT Effective date: 20250321 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250321 |
|
| T11 | Administrative time limit extension requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-T10-T11-T100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXTENSION OF TIME FOR TAKING ACTION REQUEST RECEIVED Effective date: 20250721 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20250917 |
|
| T13 | Administrative time limit extension granted |
Free format text: ST27 STATUS EVENT CODE: A-2-2-T10-T13-T101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXTENSION OF TIME FOR TAKING ACTION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20251121 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20251121 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260204 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260204 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20260408 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20260408 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260408 |